Tiffany Ho, MD
Ophthalmic Plastic and Reconstructive Surgery · Saint Louis, MONPI 1053856963
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 72.0% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $437, 2.7 times the $161 reported in 2020.
Across 43 payments — averaging $31.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$990
- Alcon$145
- Bausch & Lomb Americas Inc.$125
- Merz Pharmaceuticals, LLC$100
- Alimera Sciences, Inc.$15
What the payments were for
- Food & beverage$1,376100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 36 | $990 |
| Alcon | 2 | $145 |
| Bausch & Lomb Americas Inc. | 1 | $125 |
| Merz Pharmaceuticals, LLC | 3 | $100 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$376
- IC-8 Apthera IOL$125
- enVista MX60 IOL$125
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 48 | $1,531 |
| ErythromycinErythromycin Base | 123 | $1,303 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 37 | $469 |
| Doxycycline Monohydrate | 25 | $372 |
| Fluticasone Propionate | 12 | $178 |
| Cephalexin | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Saint Louis
- Robi MaamariSaint Louis$1K
- Christine RyuSaint Louis$711
- Rocio BentivegnaSaint Louis$150
- Michael ChappellKansas City$43K
- Nicole WestLiberty$5K
- Carisa PetrisColumbia$472
- Maria Valenzuela-ArellanoColumbia$442
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.